Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M346Revenue (TTM) $M11.9Net Margin (%)-334.8Altman Z-Score-0.6
Enterprise Value $M228EPS (TTM) $-0.9Operating Margin %-341.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score7.8Pre-tax Margin (%)-334.8Higher ROA y-yN
Price/Book6.910-y EBITDA Growth Rate %--Quick Ratio3.9Cash flow > EarningsY
Price/Sales28.55-y EBITDA Growth Rate %39.0Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow8.4y-y EBITDA Growth Rate %--ROA % (ttm)-34.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-67.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M48.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CCXI is held by these investors:



CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LUCAS ROGER CDirector 2017-02-01Sell4,000$7.32-1.91view
Cappel Markus J.Chief Bus. Officer & Treasurer 2017-01-03Sell26,821$7.51-4.39view
Bekker PetrusChief Medical Officer 2016-12-16Sell8,712$8.74-17.85view
Bekker PetrusChief Medical Officer 2016-12-05Sell30,000$8.5-15.53view
Bekker PetrusChief Medical Officer 2016-11-22Sell1,250$8.3-13.49view
Bekker PetrusChief Medical Officer 2016-11-11Sell33,332$8-10.25view
LUCAS ROGER CDirector 2016-11-01Sell4,000$6.117.7view
LUCAS ROGER CDirector 2016-09-01Sell4,000$5.0741.62view
Tyree James LDirector 2016-05-23Sell5,544$4.3963.55view
Edwards Thomas A.Director 2016-05-17Buy50,000$4.0577.28view

Press Releases about CCXI :

Quarterly/Annual Reports about CCXI:

News about CCXI:

Articles On GuruFocus.com
Immune Design Insider Buys Shares Oct 03 2016 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : March 24, 2017 Mar 24 2017
ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating... Mar 22 2017
CHEMOCENTRYX, INC. Financials Mar 18 2017
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Mar 17 2017
Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT Mar 15 2017
ChemoCentryx reports 4Q loss Mar 14 2017
ChemoCentryx reports 4Q loss Mar 14 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 14 2017
ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results Mar 14 2017
Q4 2016 ChemoCentryx Inc Earnings Release - After Market Close Mar 14 2017
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix Mar 10 2017
Sio Capital Remains Bullish On These Stocks Despite Weak Performance Mar 03 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 02 2017
ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14,... Mar 01 2017
ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference Feb 28 2017
Coverage initiated on ChemoCentryx by JMP Securities Feb 21 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 14 2017
Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases Feb 14 2017
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor... Jan 20 2017
ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the... Jan 20 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)